Not a recap. The structural principle underneath the conversation, written for operators who need to understand what's actually happening before the market makes it obvious.
Capital can buy equipment, but not years of mistakes already turned into systems and judgment. Why the best cannabis advantage may be what a company survived somewhere else.
Reform does not help every cannabis operator equally. Jay Rosenthal on why the best asset is the one that still has value when your forecast is wrong.
The first purchase carries anticipation. The second carries expectation. Kim Sanchez Rael of Azuca on why every batch has to deliver the experience again.
Curaleaf's pursuit of Aurora isn't really about cannabis. It's about 50+ tons of EU-GMP supply and the two years it takes to build it from scratch.
The federal hemp ban arrives in November. It was aimed at intoxicating products, but the language is broad enough to take therapeutic CBD with it.
Cannabis started as a medical story, then the green rush buried it. The FDA's botanical drug pathway is what brings the original thesis back.
Clean, organized data can still drive catastrophic decisions. The discount-spike loop that reads clearance as demand — and why it compounds.
Cannabis banking's hardest problem: compliance does not equal permission. Every payment solution runs on the card brands' tolerance.
Access is a transaction. Influence is leverage. Cannabis has confused the two, and the scoreboard in Washington keeps saying so.
If you've been through multiple pump-and-dump cycles, you're not early. You're just still here. Why cannabis stocks trade on plumbing, not fundamentals.
The market does not care about sunk costs. Separating the vision from the vehicles used to pursue it is the audit most leadership teams never run.
Pesticide drift means a cannabis team can do everything right and still fail testing. Vertical integration as environmental defense.
In stable industries control compounds; in unstable ones flexibility does. Cannabis infrastructure is either a moat or an anchor.
Beverage does not need to replace alcohol to matter. It only needs to capture one occasion per week. When ritual shifts, categories follow.
Cannabis marketing doesn't create value, it distributes it. If you doubled spend tomorrow, would returns scale or just expose what's broken?
Over-standardize and quality suffers. Over-index on intuition and repeatability disappears. How experienced extraction teams hold both at once.
Automation executes. Robotics adapts. Confusing the two is how cannabis companies make expensive mistakes and lock themselves into the wrong path.
Jaunty's hockey stick in New York was never luck. New York punished assumptions fast, and what looks like momentum now is really accumulated lessons.
CBD didn't earn acceptance through branding. It earned it because results showed up where nothing else worked — and Schedule III raises the bar again.
Product inconsistency costs you a customer who switches and never returns. Consistency isn't a slogan — it's engineered process control.
Schedule III put CBD first for a reason: it's the lowest-friction entry point for FDA oversight. The agency will apply the playbook it knows.
Cannabis supply chains will commoditize. Margins won't disappear — they move into manufacturing efficiency and distribution discipline.
Debt isn't the problem — the terms are. If your margins beat your cost of capital, you're not borrowing to survive, you're borrowing to win.
The gap between expectation and experience is why consumers don't return. Process control is the only way effects-based cannabis works.
Tobacco and alcohol are quietly building cannabis IP, infrastructure and data. It's not if they enter — it's when the rest of us notice.
Edibles.com quietly built one of the most intriguing cannabinoid access platforms in the country. Consumers can now shop by experience, not just by brand.
Product innovation in cannabis is a tightrope. The second-order effects — simplified SKUs, streamlined operations — are what quietly change everything.
Taxis didn't want rideshare. The world did. Every emerging industry has to earn its right to exist, and cannabis is living a version of the same story.
The disciplined operators looked slow and boring. As the debt wall closes in, the market will reward exactly one thing: prudent capital allocators.
Putting your family's name on a brand means there's nowhere to hide when things go wrong, and no shortcuts when things get hard.
Logic doesn't work in the cannabinoid space. Power and influence do. Spirits, pharma, big ag and retail are all circling the same disruption.
When billions are on the line, research gets messy. Read closely, stay skeptical — and know which meta-analysis actually put the numbers on the table.
Cannabis runs six or seven businesses at once, in multiple states, every supply chain locked to one state. Most of it is solved next door.
What if cannabis operators had to buy cannabinoids from GMP-licensed manufacturers instead of retrofitting facilities? The supply chain flips overnight.
Nobody buys wine by ABV. THC% is pushing cannabis toward commodity, and sensory science backed by data is the missing lexicon.
Dr. Greenhouse sits at the intersection of plant science, engineering, and HVAC — a rare overlap that makes her the irreplaceable expert on yield.